A Jupiter biotech firm has sold a division for $75 million, giving a big cash boost to a company on the ascendancy after a rough few years.
Dyadic International Inc. announced Tuesday that it had signed a contract to sell its industrial technology business line to chemicals giant DuPont for $75 million in cash. Following completion of the transaction, Dyadic said in a statement it plans to focus exclusively on its biopharmaceutical business.
Mark Emalfarb, Dyadic's founder and CEO, said the sale…
No comments:
Post a Comment